We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.44%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$553M
AUM Growth
+$22M
Cap. Flow
-$5.91M
Cap. Flow %
-1.07%
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.16M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$4.22M
3
AKRX
Akorn Inc
AKRX
+$3.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.21M
5
ENDP
Endo International plc
ENDP
+$2.74M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$6.62M
2
CAH icon
Cardinal Health
CAH
+$6.02M
3
MDVN
MEDIVATION, INC.
MDVN
+$4.7M
4
STJ
St Jude Medical
STJ
+$4.68M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 92.11%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$123B
$7.41M 1.34%
85,000
+19,000
+29% +$1.8M
SHPG
27
DELISTED
Shire pic
SHPG
$7.38M 1.33%
38,090
-760
-2% -$148K
ABMD
28
DELISTED
Abiomed Inc
ABMD
$7.13M 1.29%
55,450
-1,750
-3% -$210K
AKRX
29
DELISTED
Akorn Inc
AKRX
$6.87M 1.24%
252,000
+125,000
+98% +$3.7M
ARIA
30
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$6.78M 1.22%
495,000
– –
AGN
31
DELISTED
Allergan plc
AGN
$6.77M 1.22%
29,400
-5,700
-16% -$1.39M
CERN
32
DELISTED
Cerner Corp
CERN
$6.08M 1.1%
98,500
+38,500
+64% +$2.43M
ALXN
33
DELISTED
Alexion Pharmaceuticals
ALXN
$6.05M 1.09%
49,400
– –
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.01M 1.09%
65,000
– –
JNJ icon
35
Johnson & Johnson
JNJ
$609B
$5.91M 1.07%
50,000
– –
MNK
36
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$5.64M 1.02%
80,800
+33,800
+72% +$2.45M
BCR
37
DELISTED
CR Bard Inc.
BCR
$5.61M 1.01%
25,000
– –
CHRS icon
38
Coherus Oncology
CHRS
$216M
$5.41M 0.98%
202,000
-102,000
-34% -$2.78M
AMSG
39
DELISTED
Amsurg Corp
AMSG
$4.79M 0.86%
71,400
-2,600
-4% -$182K
COO icon
40
Cooper Companies
COO
$14B
$4.21M 0.76%
94,000
– –
MASI
41
DELISTED
Masimo
MASI
$4.16M 0.75%
70,000
-5,000
-7% -$282K
MCK icon
42
McKesson
MCK
$98.5B
$4M 0.72%
24,000
-2,000
-8% -$373K
NUVA
43
DELISTED
NuVasive, Inc.
NUVA
$4M 0.72%
60,000
– –
IONS icon
44
Ionis Pharmaceuticals
IONS
$8.99B
$3.96M 0.71%
108,000
– –
PRGO icon
45
Perrigo
PRGO
$1.48B
$3.94M 0.71%
42,700
-1,300
-3% -$120K
IBB icon
46
iShares Biotechnology ETF
IBB
$9.39B
$3.91M 0.71%
40,500
+15,000
+59% +$1.43M
HALO icon
47
Halozyme
HALO
$9.23B
$3.84M 0.69%
318,000
– –
ENDP
48
DELISTED
Endo International plc
ENDP
$3.83M 0.69%
190,000
+138,000
+265% +$2.74M
CYTO
49
DELISTED
Altamira Therapeutics Ltd
CYTO
$3.75M 0.68%
27
– –
ESRX
50
DELISTED
Express Scripts Holding Company
ESRX
$3.49M 0.63%
49,500
-15,500
-24% -$1.16M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2016 Portfolio in Review

As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials.

  • Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
  • Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
  • Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
  • Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
  • Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
  • Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
  • Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.